Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

AIMS: Olaparib, a potent oral poly(ADP‐ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendations. METHODS: This Phase I open‐label study asses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Rolfo, Christian, Isambert, Nicolas, Italiano, Antoine, Molife, L. Rhoda, Schellens, Jan H.M., Blay, Jean‐Yves, Decaens, Thomas, Kristeleit, Rebecca, Rosmorduc, Olivier, Demlova, Regina, Lee, Myung‐Ah, Ravaud, Alain, Kopeckova, Katerina, Learoyd, Maria, Bannister, Wendy, Locker, Gershon, de Vos‐Geelen, Judith
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444797/
https://ncbi.nlm.nih.gov/pubmed/32227355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14283
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados